伊伐布雷定降低多器官功能障碍综合征患者升高的心率
该前瞻性、对照、随机、开放标签、两组II期试验纳入70例MODS、窦性心律≥90次/分且β受体阻滞剂禁忌的患者,随机接受标准治疗±伊伐布雷定5 mg每日两次经肠给药96小时。主要终点(96小时后心率下降≥10次/分的患者百分比)两组无显著差异(P=0.147)。96小时后,对照组每日中位心率降低7次/分,伊伐布雷定组降低16次/分(P=0.014)。次要结局(血流动力学、疾病严重程度、血管升压药使用、死亡率、不良事件)均无差异。
要点
- MODS且窦性心率≥90次/分、β受体阻滞剂禁忌者,口服伊伐布雷定5 mg每日两次96小时,心率下降≥10次/分的患者比例与标准治疗无显著差异(P=0.147)。
- 96小时后每日中位心率:对照组降低7次/分,伊伐布雷定组降低16次/分,组间P=0.014。
- 伊伐布雷定对血流动力学、疾病严重程度、血管升压药使用、死亡率及不良事件等次要结局均无差异。
- 该研究为II期试验,样本量70例,主要终点未达统计学显著。
适用人群与场景
- 纳入:多器官功能障碍综合征(MODS)、窦性心律且心率至少90次/分、有β受体阻滞剂治疗禁忌证的患者。
- 场景:重症监护,肠内给药。
诊断标准与关键阈值
- 窦性心律且心率至少90次/分。
- 多器官功能障碍综合征(MODS)诊断。
- β受体阻滞剂治疗禁忌证。
处置流程与药物剂量
- 伊伐布雷定5 mg每日两次,经肠内途径给药,疗程96小时,与标准治疗联用。
- 对照组接受标准治疗。
研究设计与关键结果
- 研究类型:前瞻性、对照、随机、开放标签、两组II期试验;样本量70例。
- 主要终点:96小时后心率下降至少10次/分的患者百分比,伊伐布雷定组与对照组无显著差异(P=0.147)。
- 96小时后每日中位心率:对照组降低7次/分,伊伐布雷定组降低16次/分(P=0.014)。
- 次要结局(血流动力学、疾病严重程度、血管升压药使用、死亡率、不良事件)无差异。
证据类型、等级与局限
- 证据类型:前瞻性、随机、对照、开放标签II期试验。
- 局限:原文未报告局限性
对床旁实践的改变
- 对于MODS、窦性心率≥90次/分且β受体阻滞剂禁忌的患者,口服伊伐布雷定5 mg每日两次96小时可使每日中位心率较对照组多降低9次/分,但未显著增加心率下降≥10次/分的患者比例,且未影响血流动力学或疾病严重程度。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: A heart rate higher than 90 beats/min indicates an unfavorable prognosis for patients with multiple organ dysfunction syndrome (MODS). We sought to investigate the effect of the pacemaker current (If) inhibitor ivabradine on heart rate, hemodynamics, and disease severity among patients with MODS.
PATIENTS AND METHODS: In this prospective, controlled, randomized, open-label, two-arm phase II trial, 70 patients with MODS, a sinus rhythm of at least 90 beats/min, and contraindications to β-blocker therapy were randomly assigned to receive the standard treatment ± ivabradine (5 mg twice daily) for 96 h via the enteral route. The primary outcome was the percentage of patients with a heart rate reduction of at least 10 beats/min after 96 h. Secondary outcomes included the effect of ivabradine on hemodynamics, disease severity, vasopressor use, mortality, and adverse events.
RESULTS: There were no significant differences in the primary outcome between the ivabradine and control groups (P = 0.147). After 96 h, the daily median heart rate was reduced by 7 beats/min in the control group and by 16 beats/min in the ivabradine group (P = 0.014). No differences in secondary outcomes were observed.
CONCLUSIONS: The number of critically ill patients with MODS and a sinus rhythm of at least 90 beats/min that experienced a heart rate reduction of at least 10 beats/min after oral ivabradine treatment did not differ significantly between groups. The moderate but significant reduction of heart rate by 7 beats/min did not affect hemodynamics or disease severity.
参考来源
- Nuding S, Schröder J, Presek P, et al. Reducing Elevated Heart Rates in Patients with Multiple Organ Dysfunction Syndrome with The If (Funny Channel Current) Inhibitor Ivabradine. Shock. 2018. PMID: 28930912. doi:10.1097/SHK.0000000000000992
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。